Xbrane Biopharma Logo

Xbrane Biopharma

ISIN: SE0007789409 | Ticker: XBRANE | LEI: 5493008DKD05APTKQO39
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About Xbrane Biopharma

Company Description

Xbrane Biopharma was founded at Stockholm University 2008 by researchers Jan-Willem De Gier and Samuel Wagner together with Serendipity Ixora, run by the entrepreneurs Saeid Esmaeilzadeh and Ashkan Pouya.

The foundation of the company was a unique technology that resulted in a more cost-effective production of proteins in host cells of the form E.coli.

Xbrane’s first years were about establishing the technology platform, patent protect it and establishing the required capabilities and know-how within the organization. This was done through close collaboration with leading companies engaged in production of proteins and enzymes, where Xbrane’s technology could be applied. Many of these customers were in the pharmaceutical industry, which led the company to relatively quickly realize where the focus should be. Xbrane worked during this period with leading pharmaceutical companies, among others with MedImmune (part of AstraZeneca).

Year founded

2008

Served area

Worldwide

Headcount

74

Headquarters

Retzius väg 8, 17165 Solna – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 463,763,000.00 688,427,000.00 690,515,000.00
Noncurrent Assets N/A 89,281,000.00 127,418,000.00 176,990,000.00
Property Plant And Equipment N/A 8,166,000.00 30,622,000.00 34,830,000.00
Goodwill N/A 58,453,000.00 0.00 0.00
Intangible Assets Other Than Goodwill N/A 4,083,000.00 49,672,000.00 101,995,000.00
Other Noncurrent Receivables N/A 12,610,000.00 3,945,000.00 3,945,000.00
Current Assets N/A 374,482,000.00 561,008,000.00 513,524,000.00
Inventories N/A N/A 0.00 50,260,000.00
Trade And Other Current Receivables N/A 51,384,000.00 0.00 1,335,000.00
Other Current Receivables N/A 6,981,000.00 50,253,000.00 46,121,000.00
Cash and cash equivalents 164,197,000.00 243,139,000.00 295,180,000.00 193,994,000.00
Cash Equivalents N/A 243,139,000.00 295,180,000.00 N/A
Noncurrent Assets Or Disposal Groups Classified As Held For Sale N/A N/A 68,548,000.00 69,987,000.00
Equity And Liabilities N/A 463,763,000.00 688,427,000.00 690,515,000.00
Equity 159,352,000.00 257,709,000.00 431,741,000.00 424,888,000.00
Issued Capital N/A 4,977,000.00 5,614,000.00 6,166,000.00
Retained Earnings N/A -524,938,000.00 -713,313,000.00 -885,827,000.00
Share Premium N/A 773,724,000.00 1,134,276,000.00 1,294,227,000.00
Other Reserves N/A 3,945,000.00 5,165,000.00 N/A
Equity Attributable To Owners Of Parent N/A 257,708,000.00 431,741,000.00 424,888,000.00
Noncontrolling Interests N/A N/A 0.00 0.00
Liabilities N/A 206,055,000.00 256,686,000.00 265,626,000.00
Noncurrent Liabilities N/A 17,062,000.00 37,019,000.00 29,058,000.00
Noncurrent Provisions N/A 4,810,000.00 N/A N/A
Other Noncurrent Nonfinancial Liabilities N/A 8,257,000.00 543,000.00 0.00
Current Liabilities N/A 188,993,000.00 219,667,000.00 236,569,000.00
Trade And Other Current Payables N/A 29,546,000.00 41,393,000.00 23,297,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A 159,355,000.00 200,239,000.00
Other Current Nonfinancial Liabilities N/A 1,328,000.00 9,757,000.00 2,933,000.00
Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale N/A N/A -68,548,000.00 N/A
Liabilities Included In Disposal Groups Classified As Held For Sale N/A N/A 1,257,000.00 937,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue N/A 10,709,000.00 57,618,000.00
Other Income 17,557,000.00 4,848,000.00 20,914,000.00
Profit Loss From Operating Activities -217,436,000.00 -180,583,000.00 -166,217,000.00
Finance Costs N/A 2,643,000.00 2,296,000.00
Profit Loss Before Tax -218,126,000.00 -183,226,000.00 -168,513,000.00
Income Tax Expense Continuing Operations N/A 0.00 0.00
Profit Loss From Continuing Operations -218,126,000.00 -183,226,000.00 -168,513,000.00
Profit Loss From Discontinued Operations -7,900,000.00 -5,150,000.00 -4,001,000.00
Profit (loss) -226,026,000.00 -188,376,000.00 -172,513,000.00
Profit Loss Attributable To Owners Of Parent -226,026,000.00 -188,376,000.00 -172,513,000.00
Profit Loss Attributable To Noncontrolling Interests N/A 0.00 0.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -226,026,000.00 -188,376,000.00 -172,513,000.00
Adjustments For Decrease Increase In Inventories N/A -51,325,000.00 0.00 -50,260,000.00
Other Adjustments For Noncash Items N/A 6,247,000.00 7,180,000.00 9,327,000.00
Cash Flows From Used In Operations N/A -219,779,000.00 -181,195,000.00 N/A
Income Taxes Paid Refund Classified As Operating Activities N/A N/A 0.00 0.00
Cash Flows From Used In Operating Activities N/A -238,407,000.00 -219,610,000.00 -193,918,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 3,855,000.00 27,678,000.00 11,616,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A N/A 49,672,000.00 48,509,000.00
Cash Flows From Used In Investing Activities N/A -3,855,000.00 -77,350,000.00 -60,125,000.00
Proceeds From Changes In Ownership Interests In Subsidiaries N/A 3,000.00 0.00 551,000.00
Proceeds From Issuing Shares N/A 346,444,000.00 380,870,000.00 170,000,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 12,000.00 0.00 0.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 3,127,000.00 7,273,000.00 8,337,000.00
Cash Flows From Used In Financing Activities N/A 322,724,000.00 349,365,000.00 148,864,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 80,461,000.00 52,406,000.00 -105,179,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -1,520,000.00 1,393,000.00 4,046,000.00
Cash and cash equivalents 164,197,000.00 243,139,000.00 295,180,000.00 193,994,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
12.09.23 Karl Martin Erik Åmark Other Buy SEK 129,000.00
12.09.23 Karl Martin Erik Åmark Other Sell SEK 128,200.00
11.09.23 Karl Martin Erik Åmark Other Sell SEK 62,140.00
08.09.23 Siavash Bashiri Other Sell SEK 194,959.00
08.09.23 Karl Martin Erik Åmark Other Other SEK 968.54
08.09.23 Karl Martin Erik Åmark Other Other SEK 0.00
07.09.23 Karl Martin Erik Åmark Other Buy SEK 262,800.00
07.09.23 Siavash Bashiri Other Sell SEK 194,700.00
07.09.23 Siavash Bashiri Other Buy SEK 45,547.20
06.09.23 Siavash Bashiri Other Sell SEK 168,250.00

Capital markets information

ISIN

SE0007789409

LEI

5493008DKD05APTKQO39

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.